Proteome Sciences plc is a United Kingdom-based company. The Company is principally engaged in biomarker research and development primarily in the field of applied proteomics, using techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Through its ProteoSHOP toolkit, Proteome Sciences provides proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST& TMT), to pharma, biotechnology and diagnostic companies. The Company has research facilities in London, the United Kingdom and Frankfurt, Germany. Its subsidiaries include Proteome Sciences R&D Verwaltungs GmbH, Proteome Sciences R&D GmbH & Co. KG, Xzillion GmbH & Co. KG, Proteome Sciences, Inc., Veri-Q Inc., Phenomics Limited and Electrophoretics Limited.

Schiff Nutrition International, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah. Schiff Nutrition International, Inc. develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the United States and throughout the world. The Company offers a range of capsules, tablets and nutrition bars. Its portfolio of brands includes Schiff, Move Free, MegaRed and Tiger’s Milk, which is marketed through the mass market, including club and health food store distribution channels. The Company markets a range of specialty supplements, vitamins and minerals under the Schiff brand. The Schiff brand specialty supplements are designed to provide consumers with targeted support for their wellness efforts. Its specialty supplements include joint care products marketed under the Schiff brand, including its Move Free and Glucosamine products. Its Move Free product is one of the joint care products in the mass market channel.

Bilcare was founded in 1995 by chairman Mohan Bhandri. Billing consumers is one of the few things that Bilcare doesn't care about when it comes to pharmaceuticals. The company is a full-service pharmaceutical development company whose services include discovery and research, clinical trial supplies manufacturing and distribution, and clinical trials management. The company also develops and manufactures prescription pharmaceuticals packaging and packaging machines. Research and manufacturing facilities are in operation in India, Singapore, the UK, and the US; additional international offices are scattered around some 30 countries worldwide. Clients include GlaxoSmithKline, Johnson & Johnson, and Pfizer.

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions. It is conducting an international Phase III registration study of its lead product candidate, retaspimycin hydrochloride (IPI-504), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90), in patients with refractory gastrointestinal stromal tumors; and a Phase I/II clinical trial in patients with advanced non-small cell lung cancer. The company's developing products include IPI-504 in combination with Taxotere in Phase Ib clinical trial for patients with solid tumors; IPI-493, an orally-delivered inhibitor of Hsp90 for patients with advanced solid tumors in Phase I clinical trial; and IPI-926, a hedgehog pathway inhibitor for patients with advanced and/or metastatic solid tumors in Phase I clinical trial. Further, the company has a discovery program focusing on fatty acid amide hydrolase, an enzyme that degrades anandamide and is targeted for neuropathic pain; and developing compounds that target Bcl-2, or Bcl-2 and Bcl-xL anti-apoptotic proteins. Infinity Pharmaceuticals has strategic alliance agreements with Mundipharma International Corporation Limited and Purdue Pharmaceutical Products L.P. to develop and commercialize pharmaceutical products; and a product development and commercialization agreement with MedImmune, Inc. to develop and commercialize cancer drugs targeting Hsp90 and the hedgehog pathway.

Ranbaxy UK Ltd. company began its operations in Britain in 1994. Ranbaxy UK hopes to run the British generic pharmaceuticals market. Ranbaxy company, a subsidiary of Indian drug firm Ranbaxy Laboratories, offers a wide variety of generic drugs in the UK for central nervous system disorders, cardiovascular diseases, and anti-infectives. Some of the company's products include Easyhaler (an inhaler for respiratory problems), Visclair (for chronic obstructive pulmonary disease), and Distaclor-MR (for respiratory tract infections). Ranbaxy UK represents a major foothold for the group's operations in Europe.

Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

United Research Laboratories (URL), along with sister company Mutual Pharmaceutical (together known as URL/Mutual), manufactures generic medications and conducts research on existing drug formulas through agreements with other pharmaceutical companies. URL/Mutual has developed generic versions of drugs manufactured by King, Ortho-McNeil, Merck, and Berlex, among others. The company has also developed its own proprietary drug delivery systems. URL and Mutual Pharmaceuticals are subsidiaries of URL Pharma (formerly Pharmaceutical Holdings Corporation).

Precision Therapeutics, Inc. company was founded in 1995 and is headquartered in Pittsburgh, Pennsylvania. Precision Therapeutics, Inc., a diagnostics services company, engages in the development and delivery of treatment support tools for physicians and cancer patients in the United States and Canada. The company develops predictive drug response tests, which include ChemoFx, a drug response marker test that quantifies a cancer patient's probable tumor response to various chemotherapeutic and biologic agents and provides sensitivity and resistance information, such as tumor progression, increased side effects, accumulated toxicity, development of cross-resistance, decreased efficacy of future treatments, and decreased quality of life. It offers physicians and patients with clinical information to personalize cancer treatments.

Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing its product candidates principally for use in the hospital setting. The Company has in-licensed rights to two late stage product candidates, Acetavance a intravenous formulation of acetaminophen and Omigard (omiganan pentahydrochloride) 1% aqueous gel. It has in-licensed the exclusive United States and Canadian rights to Acetavance, that is marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company (BMS). The Company has also in-licensed the rights to commercialize Omigard in North American and Europe.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.